Evidence map›Paper›PMID 36430906›Full record

ReviewInternational journal of molecular sciences2022

Recent Advances in Nanomaterials for Asthma Treatment.

Xu Zuo, Xiaoping Guo, Yinuo Gu, Haoyu Zheng, Zhengjie Zhou, Xinlei Wang, Shengyu Jiang, Guoqiang Wang, Caina Xu, Fang Wang

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Treatment of lung diseasesMaterials today. Bio · 2025
    Review
  5. Review
  6. Nanoparticles to target asthma.American journal of physiology. Lung cellular and molecular physiology · 2024
    Review
  7. Review
  8. Article
  9. Circular RNA vaccine in disease prevention and treatment.Signal transduction and targeted therapy · 2023
    Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xu ZuoDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Xiaoping GuoDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Yinuo GuDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Haoyu ZhengDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Zhengjie ZhouDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Xinlei WangDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Shengyu JiangDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Guoqiang WangDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Caina XuDepartment of Biochemistry, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.
Fang WangDepartment of Pathogeny Biology, College of Basic Medical Sciences, Jilin University, Changchun 130021, China.ORCID 0000-0003-0871-3454
Jilin University · CN

Funding

Health Commission of Jilin Province NO. 2021JC036Jilin Provincial Development and Reform Commission Common Disease Precision Prevention and Control Engineering Laboratory NO. 3J1222527426Jilin Provincial Key Laboratory of Pathogen Biology NO. 3D5200117426Key Laboratory of Precision Infectious Diseases of Jilin Province (NO.20200601011JC)National Natural Science Foundation of China NO. 52073278
6 · The paper itself

Abstract

Asthma is a chronic airway inflammatory disease with complex mechanisms, and these patients often encounter difficulties in their treatment course due to the heterogeneity of the disease. Currently, clinical treatments for asthma are mainly based on glucocorticoid-based combination drug therapy; however, glucocorticoid resistance and multiple side effects, as well as the occurrence of poor drug delivery, require the development of more promising treatments. Nanotechnology is an emerging technology that has been extensively researched in the medical field. Several studies have shown that drug delivery systems could significantly improve the targeting, reduce toxicity and improve the bioavailability of drugs. The use of multiple nanoparticle delivery strategies could improve the therapeutic efficacy of drugs compared to traditional delivery methods. Herein, the authors presented the mechanisms of asthma development and current therapeutic methods. Furthermore, the design and synthesis of different types of nanomaterials and micromaterials for asthma therapy are reviewed, including polymetric nanomaterials, solid lipid nanomaterials, cell membranes-based nanomaterials, and metal nanomaterials. Finally, the challenges and future perspectives of these nanomaterials are discussed to provide guidance for further research directions and hopefully promote the clinical application of nanotherapeutics in asthma treatment.

Indexed as

AsthmaNanostructuresPulmonary Disease, Chronic ObstructiveHumansasthmabiomedical polymersdrug deliverynanomaterialsnanoparticles

Identifiers

PMID36430906
PMCPMC9696023
OpenAlexW4309742741

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.